One of the focal points should be the discovery of cancer treatments. The Mainz-based company agreed on Friday a strategic collaboration with the Australian state of Victoria to work together on research and development of potential mRNA-based vaccines and therapies, the company said. The mRNA technology has already been used successfully in the biotech’s corona vaccine.
A jointly run research center is to be built in Melbourne. Its main objective is to support scientists in the implementation of their research projects in clinical development.
Research capabilities to be expanded in Australia
In addition, Biontech is looking to expand its clinical research capabilities in Australia and include additional study centers to accelerate the development of therapeutic options for cancer. According to the company, Biontech’s pipeline currently includes a total of 18 product candidates in 23 ongoing clinical studies.
“BioEntainer” should also be made “Down Under”.
In addition, the company intends to support the establishment of a clinical-scale mRNA production facility for a wide range of clinical programs. Containers for production, so-called “biotainers”, are also to be built at the Melbourne site. The Australian city would thus become the company’s third own mRNA production facility outside Germany. The company has already announced the establishment of such production facilities in Africa, for example in Rwanda and Singapore.